An update on the use of tolvaptan for autosomal dominant polycystic kidney disease

Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of ch...

ver descrição completa

Detalhes bibliográficos
Autores: Müller, Roman-Ulrich U., Messchendorp, A. Lianne, Birn, Henrik, Capasso, Giovambattista, Cornec-Le Gall, Emilie|||0000-0003-1958-4459, Devuyst, Olivier|||0000-0003-3744-4767, Van Eerde, Albertien, Guirchoun, Patrick, Harris, Tess, Hoorn, Ewout J.|||0000-0002-8738-3571, Knoers, Nine V.A.M., Korst, Uwe, Mekahli, Djalila, Le Meur, Yannick, Nijenhuis, T.|||0000-0002-4375-7236, Ong, Albert C. M., Sayer, John A., Schaefer, Franz, Servais, Aaude, Tesar, Vladimir|||0000-0001-6982-0689, Torra Balcells, Roser|||0000-0001-8714-2332, Walsh, Stephen B., Gansevoort, Roon T.
Formato: artículo
Fecha de publicación:2022
País:España
Recursos:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:284195
Acesso em linha:https://ddd.uab.cat/record/284195
https://dx.doi.org/urn:doi:10.1093/ndt/gfab312
Access Level:acceso abierto
Palavra-chave:ADPKD
Polycystic kidney disease
Position statement
Tolvaptan
Vasopressin V2 receptor antagonist
Descrição
Resumo:Approval of the vasopressin V2 receptor antagonist tolvaptan-based on the landmark TEMPO 3:4 trial-marked a transformation in the management of autosomal dominant polycystic kidney disease (ADPKD). This development has advanced patient care in ADPKD from general measures to prevent progression of chronic kidney disease to targeting disease-specific mechanisms. However, considering the long-Term nature of this treatment, as well as potential side effects, evidence-based approaches to initiate treatment only in patients with rapidly progressing disease are crucial. In 2016, the position statement issued by the European Renal Association (ERA) was the first society-based recommendation on the use of tolvaptan and has served as a widely used decision-making tool for nephrologists. Since then, considerable practical experience regarding the use of tolvaptan in ADPKD has accumulated. More importantly, additional data from REPRISE, a second randomized clinical trial (RCT) examining the use of tolvaptan in later-stage disease, have added important evidence to the field, as have post hoc studies of these RCTs. To incorporate this new knowledge, we provide an updated algorithm to guide patient selection for treatment with tolvaptan and add practical advice for its use.

Registos relacionados